title: Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites.
abstract: The pharmacokinetics of oxaliplatin in plasma and ascitic fluid was investigated in 5 gastrointestinal cancer patients with malignant ascites. Oxaliplatin was administered at 85 mg/m² by 2-hour infusion in the FOLFOX4 regimen, and the concentrations of total and free platinum were measured. There was a trend of lower plasma C(max) values of total platinum in patients with a larger volume of ascitic fluid. The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively. The concentrations of free ascites platinum were similar to those of free plasma platinum at the last sampling time of 26 h in each patient. The decrease or disappearance of ascitic fluid was observed in 4 patients. These results suggest that oxaliplatin exerted a beneficial effect in gastrointestinal cancer patients with malignant ascites, even when administered intravenously.
authors.affiliation: Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. gann@med.nihon-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Kochi
authors.forename: M
authors.initials: M
authors.lastname: Fujii
authors.forename: N
authors.initials: N
authors.lastname: Kanamori
authors.forename: T
authors.initials: T
authors.lastname: Kaiga
authors.forename: R
authors.initials: R
authors.lastname: Okubo
authors.forename: Y
authors.initials: Y
authors.lastname: Mihara
authors.forename: T
authors.initials: T
authors.lastname: Takayama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001201:Ascites / Q000097:blood / Q000378:metabolism / Q000473:pathology; D001202:Ascitic Fluid / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010984:Platinum / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010984:Platinum; D002955:Leucovorin; D005472:Fluorouracil